The FDA granted clearance for Tianjin Huahong Technology's safety lancet, a Class II device intended for single-use blood sampling.
Tianjin Huahong Technology Co., Ltd. has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Safety Lancet (XL). The decision, issued on September 13, 2026, classifies the device as substantially equivalent to existing predicate devices.
This clearance allows Tianjin Huahong to market its Safety Lancet (XL) in the United States. The device falls under product code FMK, which pertains to medical lancets. It is classified as a Class II medical device, indicating a moderate level of regulatory control deemed necessary to assure the safety and effectiveness of the device.
Device Classification and Regulatory Pathway
The Safety Lancet (XL) operates under regulation number 878.4850, a classification for general-purpose medical lancets. These devices are typically used to puncture the skin to obtain capillary blood samples for various diagnostic purposes, such as glucose monitoring or other point-of-care tests. The traditional 510(k) clearance pathway utilized by Tianjin Huahong required demonstrating that the device is as safe and effective as a legally marketed predicate device.
The FDA's review was conducted by the General, Plastic Surgery advisory committee, consistent with the broad applications of such devices in healthcare settings. The clearance was based on a summary submission, meaning a detailed premarket notification was filed, but a full 510(k) Premarket Notification is not yet publicly available in its entirety.
Market Context and Implications
Safety lancets are designed to minimize accidental needlestick injuries for both patients and healthcare professionals, typically incorporating features like automated retraction mechanisms. While the specific design features and technical specifications of Tianjin Huahong's Safety Lancet (XL) are not detailed in the publicly available clearance record, the 'XL' designation may imply variations in gauge, depth, or design for specific patient populations or sampling needs. The market for safety lancets is mature and competitive, with numerous established manufacturers.
The clearance signifies Tianjin Huahong's entry or expansion into the U.S. market for blood sampling devices. Further details regarding the device's specific applications, distribution strategy, and commercial launch plans have not been disclosed by the company.
